Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Dr
06 Maio 2008 - 9:30AM
PR Newswire (US)
ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs,
announced today the completion of a Service Agreement with
Concordia Pharmaceuticals, Inc. and initiation of preclinical
studies to evaluate new applications for Salirasib using Champions
Biotechnology's Biomerk Tumorgrafts(TM). "Our Biomerk Tumorgraft
preclinical platform and its benefits in drug discovery and
evaluation is gaining recognition as we expand our platform to
pharmaceutical and biotech companies" said Doug Burkett, Ph.D.,
President of Champions Biotechnology, Inc. "Champions is in a
unique position to evaluate oncology drugs as well as novel drug
combinations that may be effective in treating specific cancer
types. We are pleased to be assisting Concordia Pharmaceuticals in
the evaluation of new preclinical applications for Salirasib, a
Ras-antagonist that acts to inhibit cancer by impairing the
disease's ability to replicate defective cells." For more
information regarding Champions Biotechnology's growing business
and recent news, please visit
http://www.championsbiotechnology.com/. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and predictive tumor
specific data to enhance and accelerate the value of oncology
drugs. The Company's Preclinical Platform is a novel approach based
upon the implantation of primary human tumors in immune deficient
mice followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. The Company believes
that these Tumorgrafts closely reflect human cancer biology and
their response to drugs is more predictive of clinical outcomes in
cancer patients. Champions Biotechnology leverages its preclinical
platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates through pre-clinical trials. As drugs
progress through this early stage of development, the Company plans
to sell, partner or license them to pharmaceutical and/or
biotechnology companies, as appropriate. The Company also offers
its predictive preclinical platform and tumor specific data to
physicians for personalized patient care. In the course of this
process, this permits the Company to evaluate oncology drugs for
companies by using models that integrate prognostic testing with
biomarker discovery. Champions Biotechnology is dedicated to
enhancing preclinical development tools, accelerating development
and valuation of oncology drugs, and advancing personalized
treatment with a goal to improve the lives of cancer patients
globally. This press release contains "forward-looking statements"
(within the meaning of the Private Securities Litigation Act of
1995) that inherently involve risk and uncertainties. Champions
Biotechnology generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and
similar expressions to identify forward-looking statements. One
should not place undue reliance on these forward-looking
statements. The Company's actual results could differ materially
from those anticipated in the forward-looking statements for many
unforeseen factors. See Champions Biotechnology's Form 10-KSB for
the fiscal year ended April 30, 2007 for a discussion of such
risks, uncertainties and other factors. Although the Company
believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions
Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not
intend to update any of the forward-looking statements after the
date of this press release to conform these statements to actual
results or to changes in Champions Biotechnology's expectations,
except as required by law. DATASOURCE: Champions Biotechnology
CONTACT: James Martell of Champions Biotechnology, +1-410-630-1313
Web site: http://www.championsbiotechnology.com/
Copyright